Abbott Laboratories Announces Strong Q1 2025 Financial Results

Abbott Laboratories has reported a significant increase in its first-quarter revenue for 2025, reaching $10.4 billion, a 4% rise compared to the previous year. The company's net earnings soared to $1.3 billion, marking an 8.2% year-on-year growth, with diluted earnings per share (EPS) climbing 8.6% to $0.76.

CEO Robert Ford highlighted the company's diversified business model as a key driver behind this success, stating, "Abbott's ability to deliver top-tier sales and EPS growth, even in uncertain times, underscores our commitment to sustainable growth." The company remains optimistic about its 2025 outlook, reaffirming its guidance for organic sales growth between 7.5% and 8.5%, an adjusted operating margin of 23.5% to 24.0%, and adjusted diluted EPS ranging from $5.05 to $5.25.